News

An anti-inflammatory diet was linked to a lower risk of bladder cancer, including a 65% lower risk of muscle-invasive disease.

A Phase 3 clinical trial of UGN-102 in low-grade intermediate-risk non-muscle invasive bladder cancer supports its long-term efficacy.

A large study shows that tumors in the bladder neck or trigone increase the risk of bladder cancer returning or advancing to a later stage.

Erda-iDRS uses a device in the bladder to release erdafitinib, and achieved an 89% complete response rate in intermediate-risk disease.

Doctors should plan follow-up care for patients with intermediate-risk non-muscle-invasive bladder cancer based on each person’s needs.

A protein called LTBP1 appears to drive resistance to cisplatin in bladder cancer and is linked to more advanced disease and poorer survival.

Over the past 20 years deaths from bladder cancer in the U.S. have gone down, but sex, race and region still influence who is more likely to die.

A new study shows how AI and inflammation markers provide a personalized look at survival for patients following bladder cancer surgery.

A recent study found low vitamin D levels are associated with a 32% higher risk of developing bladder cancer.

The FDA is reviewing information on a possible new treatment for papillary bladder cancer that does not respond to the standard treatment.